Apolipoproteins in obesity: effect of weight loss
Related Experiment Video
Updated: Sep 30, 2026

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
V V Gossain1, K P Gunaga, M J Carella
1Department of Medicine, Michigan State University, East Lansing 48824, USA.
Abstract:
We evaluated serum concentrations of apoprotein (APO) A1, B, total cholesterol, triglycerides, high density cholesterol (HDL-C), and low density cholesterol (LDL-C) in twelve obese subjects whose body mass index (BMI) was > or = 30 before and after a clinically significant weight loss was obtained utilizing a very-low calorie diet (VLCD) consisting of liquid protein (Optifast) providing 800 calories a day. At baseline, the mean weight +/- SD was 119.77 Kg and decreased significantly to 89.29 +/- 13.46 Kg by 24 weeks. Statistically significant reductions of APO-A1, APO-B, total cholesterol, and triglyceride concentrations were also observed along with the weight loss. LDL-C decreased from 156.0 +/- 55.9 mg/dL to 122.5 +/- 42.2 mg/dL (4.03 +/- 1.4 to 3.16 +/- 1.1 mmol/L), but this difference was not statistically significant. There was no significant change in the HDL-C and the ratios of APO-A1 to APO-B. We conclude that the use of VLCD is associated with changes in the lipid pattern that lower the cardiovascular risk profile in addition to the beneficial effects of weight loss itself.
More Related Videos
03:05Influence of Emotional Factors on the Efficacy of Acupuncture Treatment for Overweight Complicated with Hyperlipidemia: A Retrospective Cohort Study
Published on: November 21, 2025
10:40Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Regulation of Food Intake
Obesity
Drug Dosing: Obese Patients
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion